December 7, 2021
Bavarian Nordic A/S issues 6,373,680 New Ordinary Shares
Bavarian Nordic A/S (“Bavarian Nordic” or the “Company”) announced its intention to raise new capital through an accelerated bookbuilding process.…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Bavarian Nordic
March 22, 2021
Bavardian Nordic nets $31.2M deal with Public Health Agency of Canada
Bavarian Nordic got a $31.2million worth of Imvamune vaccines order from Public Health Agency of Canada (PHAC).
September 25, 2019
FDA grants approval for Bavarian Nordic’s monkeypox vaccine
The FDA granted the approval of Jynneos for the prevention of monkeypox disease, to Bavarian Nordic A/S, and it granted the application Priority Review, it said Tuesday in a press release.
January 18, 2019
Bavarian Nordic gets U.S. Government $44M option exercised for Contract for Freeze-dried MVA-BN smallpox vaccine
Bavarian Nordic said Friday that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has exercised $44 million option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine.
May 31, 2018
New CFO to join Bavarian Nordic
Bavarian Nordic has appointed new Chief Financial Officer, coming from a Nasdaq Stockholm exchange listed pharmaceutical company, Orexo AB, it said…
January 19, 2018
Bavarian Nordic kicks-off cancer candidate trial
Bavarian Nordic said Friday that it has kicked off a clinical trial of BN-Brachyury, a novel cancer immunotherapy candidate designed…
July 27, 2017
Bavarian Nordic to receive milestone payments up to $836 million from Janssen
Bavarian Nordic has announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals, which grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two programs, targeting vaccines against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1).
January 17, 2017
Bavarian Nordic appoints Henrik Birk as COO
Bavarian Nordic has appointed Henrik Birk as Chief Operating Officer, the newly created position where he will develop and lead the execution of Bavarian Nordic’s operational and HR strategies.
December 22, 2015
Janssen and Bavarian Nordic to develop vaccine for Chronic Human Papillomavirus (HPV) infections
Janssen Pharmaceuticals, Inc. (Janssen) has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.